Downes, Damien J. http://orcid.org/0000-0002-5034-0869
Beagrie, Robert A. http://orcid.org/0000-0003-1076-5595
Gosden, Matthew E. http://orcid.org/0000-0002-0657-7666
Telenius, Jelena
Carpenter, Stephanie J.
Nussbaum, Lea
De Ornellas, Sara
Sergeant, Martin
Eijsbouts, Chris Q.
Schwessinger, Ron http://orcid.org/0000-0001-7829-8503
Kerry, Jon
Roberts, Nigel http://orcid.org/0000-0002-5091-3604
Shivalingam, Arun
El-Sagheer, Afaf http://orcid.org/0000-0001-8706-1292
Oudelaar, A. Marieke http://orcid.org/0000-0002-4016-6158
Brown, Tom http://orcid.org/0000-0002-6538-3036
Buckle, Veronica J. http://orcid.org/0000-0003-1195-2608
Davies, James O. J. http://orcid.org/0000-0002-4108-4357
Hughes, Jim R. http://orcid.org/0000-0002-8955-7256
Funding for this research was provided by:
Wellcome Trust (203141/Z/16/Z, 106130/Z/14/Z)
U.S. Department of Health & Human Services | National Institutes of Health (R24DK106766)
RCUK | Medical Research Council (MC_UU_00016, MR/N00969X/1)
Article History
Received: 6 April 2020
Accepted: 16 December 2020
First Online: 22 January 2021
Competing interests
: J.R.H. and J.O.J.D. are founders and shareholders of Nucleome Therapeutics. D.J.D. and R.S. are paid consultants of Nucleome Therapeutics. No other authors have competing interests.